News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Articles|September 13, 2017

Self-Disclosure by Psychiatrists

Author(s)H. Steven Moffic, MD

How much should you reveal about yourself to your patients? To colleagues? To the state medical society? H. Steven Moffic, MD, takes a look at this issue in this video.

How much should you reveal about yourself to your patients? To colleagues? To the state medical society? H. Steven Moffic, MD, takes a look at this issue in this video.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

strike

Striking a Balance: What Consultation-Liaison Psychiatrists Should Know About the Hospital Psychological Milieu During a Strike

ByAdrienne D. Mishkin, MD, MPH, MS,Sara S. Nash, MD,Christina Kitt Garza, MD

March 11th 2026

mentoring

On Mentoring

ByJohn J. Miller, MD

October 9th 2025

wilted flowers

Spare Me the Bouquets: The Growing Crisis of Being a Doctor in India

ByHarneet Kaur, MD

July 1st 2025

sad med student

Walking the Line: Navigating Student Mistreatment by Patients

ByMadeline Hawkins,Julie Williams, MD, MS

June 24th 2025

HappyAprilBoy/AdobeStock

A Love Letter to My Workplace: An Ethical Model of Private Practice for Clinician and Patient Well-Being

ByLayne A. Gritti, DO

February 10th 2025

Latest CME

Southern California Psychiatry Conference

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

The Top 10 Misleading Claims About Antidepressants

Positive Phase 3 Data for Centanafadine to Treat Comorbid ADHD and Anxiety

What Does July 4th Mean for Patients? A Psychiatric Perspective on Holiday Vulnerability

Podcast: Deprescribing Insights From an ASCP Panel of Psychiatric Experts

Potential of GABAergic Medications in MDD